Texas Permanent School Fund Corp Sells 11,931 Shares of Certara, Inc. (NASDAQ:CERT)

Texas Permanent School Fund Corp lowered its position in shares of Certara, Inc. (NASDAQ:CERT) by 12.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 81,798 shares of the company’s stock after selling 11,931 shares during the quarter. Texas Permanent School Fund Corp owned about 0.05% of Certara worth $1,133,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Mubadala Investment Co PJSC bought a new position in shares of Certara during the 4th quarter worth about $169,135,000. Wasatch Advisors LP boosted its position in shares of Certara by 23.4% during the 1st quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after purchasing an additional 932,598 shares in the last quarter. Norges Bank bought a new position in shares of Certara during the 4th quarter worth about $14,262,000. Geneva Capital Management LLC boosted its position in shares of Certara by 15.1% during the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after purchasing an additional 579,349 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. boosted its position in shares of Certara by 93.1% during the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 769,300 shares of the company’s stock worth $13,532,000 after purchasing an additional 370,820 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Robert W. Baird cut their price objective on shares of Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Barclays lowered their target price on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. JMP Securities restated a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. UBS Group lowered their target price on shares of Certara from $20.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. Finally, KeyCorp lowered their target price on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Seven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Certara currently has a consensus rating of “Hold” and an average target price of $17.79.

Insider Transactions at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares in the company, valued at approximately $1,125,658.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 2.39% of the stock is currently owned by company insiders.

Certara Trading Down 3.6 %

NASDAQ:CERT opened at $10.90 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61. The firm has a market cap of $1.75 billion, a price-to-earnings ratio of -27.95, a price-to-earnings-growth ratio of 5.23 and a beta of 1.49. Certara, Inc. has a 52 week low of $10.35 and a 52 week high of $19.87. The firm has a 50-day moving average price of $13.26 and a two-hundred day moving average price of $15.40.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The company had revenue of $93.31 million for the quarter, compared to analysts’ expectations of $96.01 million. During the same quarter in the previous year, the business earned $0.10 EPS. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, equities analysts expect that Certara, Inc. will post 0.27 earnings per share for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.